Epidemiology of pancreatic cancer and the role of family history

Journal of Surgical Oncology

Volumn 107, Issue 1, 2013, Pages 1-7

  Olson, Sara H ^a   Kurtz, Robert C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

allergies; diabetes; epidemiology; genetic syndromes; obesity; smoking

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ALCOHOL CONSUMPTION; ASTHMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; DIABETES MELLITUS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GENDER; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERM LINE; HAY FEVER; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MISMATCH REPAIR; OBESITY; PANCREAS ADENOMA; PANCREAS CANCER; PANCREATITIS; PARTNER AND LOCALIZER OF BRCA2 GENE; PEUTZ JEGHERS SYNDROME; POLLEN ALLERGY; PRIORITY JOURNAL; RACE; REVIEW; SMOKING; TUMOR SUPPRESSOR GENE;

AGED; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; PANCREATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84871262457     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23149     Document Type: Review

References (89)

1. American Cancer Society: Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.
2. Howlader N, Noone A, Krapcho M, et al.: SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute; http://seercancergov/csr/ 1975-2008/ based on November 2010 SEER data submission, posted to the SEER web site, 2011.
3. Fast Stats: An interactive tool for access to SEER cancer statistics: Surveillance Research Program, National Cancer Institute. In: http://seer.cancer.gov/faststats. (Accessed on 4-10-2012).
4. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
5. Olson SH, Layne TM, Simon JA, et al.: Studying cancer in minorities: A look at the numbers. Cancer 2011; 117: 2762-2769.
6. Silverman DT, Hoover RN, Brown LM, et al.: Why do Black Americans have a higher risk of pancreatic cancer than White Americans ? Epidemiology 2003; 14: 45-54.
7. Iodice S, Gandini S, Maisonneuve P, et al.: Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbeck's archives of surgery/Deutsche Gesellschaft fur Chirurgie 2008; 393: 535-545.
8. Lynch SM, Vrieling A, Lubin JH, et al.: Cigarette smoking and pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170: 403-413.
9. Bosetti C, Lucenteforte E, Silverman DT, et al.: Cigarette smoking and pancreatic cancer: An analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2011; [epub ahead of print].
10. Tranah GJ, Holly EA, Wang F, et al.: Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: A population-based study in the San Francisco Bay Area. BMC Cancer 2011; 11: 138.
11. Heinen MM, Verhage BA, Goldbohm RA, et al.: Active and passive smoking and the risk of pancreatic cancer in the Netherlands Cohort Study. Cancer Epidemiol Biomarkers Prev 2010; 19: 1612-1622.
12. Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, et al.: Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2010; 126: 2394-2403.
13. Calle EE, Rodriguez C, Walker-Thurmond K, et al.: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
14. Genkinger JM, Spiegelman D, Anderson KE, et al.: A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 2011; 129: 1708-1717.
15. Li D, Morris JS, Liu J, et al.: Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301: 2553-2562.
16. Arslan AA, Helzlsouer KJ, Kooperberg C, et al.: Anthropometric measures, body mass index, and pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010; 170: 791-802.
17. Jiao L, Berrington de Gonzalez A, Hartge P, et al.: Body mass index, effect modifiers, and risk of pancreatic cancer: A pooled study of seven prospective cohorts. Cancer Causes Control 2010; 21: 1305-1314.
18. Friedenreich CM, Cook LS, Magliocco AM, et al.: Case-control study of lifetime total physical activity and endometrial cancer risk. Cancer Causes Control 2010; 21: 1105-1116.
19. Ben Q, Xu M, Ning X, et al.: Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47: 1928-1937.
20. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, et al.: Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005; 92: 2076-2083.
21. Li D, Tang H, Hassan MM, et al.: Diabetes and risk of pancreatic cancer: A pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22: 189-197.
22. Pannala R, Leibson CL, Rabe KG, et al.: Temporal association of changes in fasting blood glucose and body mass index with diagnosis of pancreatic cancer. Am J Gastroenterol 2009; 104: 2318-2325.
23. Lee MS, Hsu CC, Wahlqvist ML, et al.: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: A representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11: 20.
24. Currie CJ, Poole CD, Gale EA:, The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
25. Bodmer M, Becker C, Meier C, et al.: Use of antidiabetic agents and the risk of pancreatic cancer: A case-control analysis. Am J Gastroenterol 2012; 107: 620-626.
26. Olson SH:, Selected medical conditions and risk of pancreatic cancer. Mol Carcinog 2012; 51: 75-97.
27. Talamini G, Falconi M, Bassi C, et al.: Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999; 94: 1253-1260.
28. Lowenfels AB, Maisonneuve P, Cavallini G, et al.: Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328: 1433-1437.
29. Karlson BM, Ekbom A, Josefsson S, et al.: The risk of pancreatic cancer following pancreatitis: An association due to confounding ? Gastroenterology 1997; 113: 587-592.
30. Duell EJ:, Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol Carcinog 2012; 51: 40-52.
31. Lucenteforte E, La Vecchia C, Silverman D, et al.: Alcohol consumption and pancreatic cancer: A pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23: 374-382.
32. Genkinger JM, Spiegelman D, Anderson KE, et al.: Alcohol intake and pancreatic cancer risk: A pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev 2009; 18: 765-776.
33. Wang H, Diepgen TL:, Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 2005; 60: 1098-1111.
34. Turner MC, Chen Y, Krewski D, et al.: An overview of the association between allergy and cancer. Int J Cancer 2006; 118: 3124-3132.
35. Gandini S, Lowenfels AB, Jaffee EM, et al.: Allergies and the risk of pancreatic cancer: A meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiol Biomarkers Prev 2005; 14: 1908-1916.
36. Olson SH, Orlow I, Simon J, et al.: Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect Prev 2007; 31: 345-351.
37. Lo AC, Soliman AS, El-Ghawalby N, et al.: Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk. Pancreas 2007; 35: 120-129.
38. Anderson LN, Cotterchio M, Gallinger S:, Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes Control 2009; 20: 825-834.
39. Maisonneuve P, Lowenfels AB, Bueno-de-Mesquita HB, et al.: Past medical history and pancreatic cancer risk: Results from a multicenter case-control study. Ann Epidemiol 2010; 20: 92-98.
40. Turner MC, Chen Y, Krewski D, et al.: Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 2005; 162: 212-221.
41. Lindelof B, Granath F, Tengvall-Linder M, et al.: Allergy and cancer. Allergy 2005; 60: 1116-1120.
42. Eriksson NE, Holmen A, Hogstedt B, et al.: A prospective study of cancer incidence in a cohort examined for allergy. Allergy 1995; 50: 718-722.
43. McWhorter WP:, Allergy and risk of cancer. A prospective study using NHANES I followup data. Cancer 1988; 62: 451-455.
44. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al.: Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41: 986-990.
45. Macafee AL:, ABO blood groups and carcinoma of pancreas. Ulster Med J 1964; 33: 129-131.
46. Aird I, Lee DR, Roberts JA:, ABO blood groups and cancer of oesophagus, cancer of pancreas, and pituitary adenoma. Br Med J 1960; 1: 1163-1166.
47. Wolpin BM, Kraft P, Gross M, et al.: Pancreatic cancer risk and ABO blood group alleles: Results from the pancreatic cancer cohort consortium. Cancer Res 2010; 70: 1015-1023.
48. Risch HA:, Pancreatic cancer: Helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Mol Carcinog 2012; 51: 109-118.
49. Trikudanathan G, Philip A, Dasanu CA, et al.: Association between Helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. JOP 2011; 12: 26-31.
50. Petersen GM, Amundadottir L, Fuchs CS, et al.: A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010; 42: 224-228.
51. Wu C, Miao X, Huang L, et al.: Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet 2012; 44: 62-66.
52. Low SK, Kuchiba A, Zembutsu H, et al.: Genome-wide association study of pancreatic cancer in Japanese population. PLoS Genet 2010; 5: e11824.
53. Pierce BL, Ahsan H:, Genome-wide "pleiotropy scan" identifies HNF1A region as a novel pancreatic cancer susceptibility locus. Cancer Res 2011; 71: 4352-4358.
54. Ehrenthal D, Haeger L, Griffin T, et al.: Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987; 59: 1661-1664.
55. Lynch HT, Voorhees GJ, Lanspa SJ, et al.: Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: A family study. Br J Cancer 1985; 52: 271-273.
56. Hruban RH, Canto MI, Goggins M, et al.: Update on familial pancreatic cancer. Adv Surg 2010; 44: 293-311.
57. Jacobs EJ, Chanock SJ, Fuchs CS, et al.: Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010; 127: 1421-1428.
58. Tersmette AC, Petersen GM, Offerhaus GJ, et al.: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738-744.
59. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999; 91: 1310-1316.
60. Murphy KM, Brune KA, Griffin C, et al.: Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62: 3789-3793.
61. Lynch HT, Deters CA, Snyder CL, et al.: BRCA1 and pancreatic cancer: Pedigree findings and their causal relationships. Cancer Genet Cytogenet 2005; 158: 119-125.
62. Thompson D, Easton DF:, Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365.
63. Rahman N, Seal S, Thompson D, et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-167.
64. Tischkowitz MD, Sabbaghian N, Hamel N, et al.: Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009; 137: 1183-1186.
65. Jones S, Hruban RH, Kamiyama M, et al.: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
66. Lynch HT, Lanspa SJ, Boman BM, et al.: Hereditary nonpolyposis colorectal cancer-Lynch syndromes I and II. Gastroenterol Clin N Am 1988; 17: 679-712.
67. Umar A, Boland CR, Terdiman JP, et al.: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268.
68. Geary J, Sasieni P, Houlston R, et al.: Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 2008; 7: 163-172.
69. Kastrinos F, Mukherjee B, Tayob N, et al.: Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302: 1790-1795.
70. Yamamoto H, Itoh F, Nakamura H, et al.: Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001; 61: 3139-3144.
71. Goldstein AM:, Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004; 23: 630.
72. Bergman W, Watson P, de Jong J, et al.: Systemic cancer and the FAMMM syndrome. Br J Cancer 1990; 61: 932-936.
73. Bergman W, Gruis N:, Familial melanoma and pancreatic cancer. N Engl J Med 1996; 334: 471-472.
74. Vasen HF, Gruis NA, Frants RR, et al.: Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87: 809-811.
75. Vasen HF, Wasser M, van Mil A, et al.: Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 2011; 140: 850-856.
76. Giardiello FM, Trimbath JD:, Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4: 408-415.
77. Giardiello FM, Welsh SB, Hamilton SR, et al.: Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316: 1511-1514.
78. Hearle N, Schumacher V, Menko FH, et al.: Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12: 3209-3215.
79. Giardiello FM, Offerhaus GJ, Lee DH, et al.: Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34: 1394-1396.
80. Groen EJ, Roos A, Muntinghe FL, et al.: Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008; 15: 2439-2450.
81. Lowenfels AB, Maisonneuve P, DiMagno EP, et al.: Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89: 442-446.
82. Whitcomb DC, Gorry MC, Preston RA, et al.: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14: 141-145.
83. Whitcomb DC, Preston RA, Aston CE, et al.: A gene for hereditary pancreatitis maps to chromosome 7q35. Gastroenterology 1996; 110: 1975-1980.
84. Greenhalf W, Malats N, Nilsson M, et al.: International registries of families at high risk of pancreatic cancer. Pancreatology 2008; 8: 558-565.
85. Canto MI, Goggins M, Yeo CJ, et al.: Screening for pancreatic neoplasia in high-risk individuals: An EUS-based approach. Clin Gastroenterol Hepatol 2004; 2: 606-621.
86. Canto MI, Goggins M, Hruban RH, et al.: Screening for early pancreatic neoplasia in high-risk individuals: A prospective controlled study. Clin Gastroenterol Hepatol 2006; 4: 766-781; quiz 665.
87. Ludwig E, Olson SH, Bayuga S, et al.: Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106: 946-954.
88. Langer P, Kann PH, Fendrich V, et al.: Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58: 1410-1418.
89. Brand RE, Lerch MM, Rubinstein WS, et al.: Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56: 1460-1469.